The use of feline herpesvirus and baculovirus as vaccine vectors for the gag and env genes of feline leukaemia virus

References

1. Akerblom L., Stromstedt S., Hoglund S., Osterhaus A., Morein B. 1989; Formation and characterization of FeLV ISCOMs. Vaccine 7:142–146
   [Google Scholar]
2. Cole G. E., Stacy-Phipps S., Nunberg J. H. 1990; Recombinant feline herpesvirus expressing feline leukemia virus envelope and gag proteins. Journal of Virology 64:4930–4938
   [Google Scholar]
3. De Noronha F., Grant C. K., Lutz H., Keyes A., Rouston W. 1983; Circulating levels of feline leukemia and sarcoma viruses and fibrosarcoma regression in persistently viremic cats. Cancer Research 43:1663–1668
   [Google Scholar]
4. Donahue P. R., Hoen R. A., Belts G. A., Riedel N., Hirsch V. M., Overbaug J., Mullins J. 1988; Strong sequence conservation among horizontally transmissible minimally pathogenic feline leukemia viruses. Journal of Virology 62:722–731
   [Google Scholar]
5. Flyer D. C., Burakoff S. J., Faller D. V. 1983; Cytotoxic T lymphocyte recognition of transfected cells expressing a cloned retroviral gene. Nature London 305:815–818
   [Google Scholar]
6. Francis D. P., Essex M., Hardy W. D. 1977; Excretion of feline leukaemia virus by naturally infected pet cats. Nature, London 269:252–254
   [Google Scholar]
7. Gaskell R. M., Povey R. C. 1979; The dose reponse of cats to experimental infection with feline rhinotracheitis virus. Journal of Comparative Pathology 89:179–191
   [Google Scholar]
8. Germain R. N. 1986; The ins and outs of antigen processing and presentation. Nature, London 322:687–689
   [Google Scholar]
9. Grant C. K., de Noronha F., Tusch C., Michalek M. T., McLane M. F. 1980a; Protection of cats against progressive firbrosarcoma and persistent leukemia virus infection by vaccination with feline leukemia cells. Journal of the National Cancer Institute 65:1285–1292
   [Google Scholar]
10. Grant C. K., Essex M., Gardner M. B., Hardy W. D. 1980b; Natural feline leukemia virus infection and the immune response of cats of different ages. Cancer Research 40:832–398
    [Google Scholar]
11. Grant C. K., Ernisee B. J., Jarrett O., Jones F. R. 1983; Feline leukemia virus envelope gp70 of subgroups B and C defined by monoclonal antibodies with cytotoxic and neutralizing functions. Journal of Immunology 131:3042–3048
    [Google Scholar]
12. Halstead S. B. 1988; Pathogenesis of dengue: challenges to molecular biology. Science 239:476–481
    [Google Scholar]
13. Hardy W. D. 1980; The virology, immunology and epidemiology of the feline leukemia virus. In Feline Leukemia Virus pp 33–78 Edited by Hardy W. D., Essex M., McClelland A. J. Amsterdam: Elsevier;
    [Google Scholar]
14. Hardy W. D., Old L. J., Hess P. W., Essex M., Cotter S. 1973; Horizontal transmission of feline leukaemia virus. Nature, London 244:266–267
    [Google Scholar]
15. Holt C. A., Osorio K., Lilly F. 1986; Friend virus-specific cytotoxic T lymphocytes recognize both gag and env gene-encoded specificities. Journal of Experimental Medicine 164:211–226
    [Google Scholar]
16. Jarrett W. F. H., Crawford E. M., Martin W. B., Davie F. 1964; A virus-like particle associated with leukaemial lymphosarcoma. Nature, London 2JS/2567–569
    [Google Scholar]
17. Jarrett W., Jarrett O., Mackey L., Laird H., Hood C., Hay D. 1975; Vaccination against feline leukemia virus using a cell membrane antigen system. International Journal of Cancer 16:134–140
    [Google Scholar]
18. Jeggo M. H., Wardley R. C. 1982; Generation of cross-reactive cytotoxic T lymphocytes following immunization of mice with various bluetongue virus types. Immunology 45:629–636
    [Google Scholar]
19. Kimman T. G., Westenbrink F., Straw P. J. 1989; Priming for lead and systemic antibody memory responses to bovine respiratory syncytial virus: effect of amount of virus replication, route of administration and material antibodies. Veterinary Immunology and Immunopathology 22:145–160
    [Google Scholar]
20. Kit M., Kit S., Little S. P., Di Marchi R. D., Gale C. 1991; Bovine herpesvirus-1 (infectious bovine rhinotracheitis virus)-based viral vector which expresses foot-and-mouth disease epitopes. Vaccine 9:564–572
    [Google Scholar]
21. Lewis M. G., Mathes L. E., Olsen R. G. 1981; Protection against feline leukemia by vaccination with a subunit vaccine. Infections and Immunity 34:888–893
    [Google Scholar]
22. Lutz H., Pedersen N., Higgins J., Hubscher U., Troy F. A., Theilen G. H. 1980; Humoral immune reactivity to feline leukemia virus and associate antigens in cats naturally infected with feline leukemia virus. Cancer Research 40:3642–3651
    [Google Scholar]
23. Lycke N., Hellstrom U., Holmgren J. 1987; Circulating cholera antitoxin memory cells in the blood one year after oral cholera vaccination in humans. Scandinavian Journal of Immunology 26:207–211
    [Google Scholar]
24. McCarty J. M., Grant C. K. 1983; Feline cytotoxic immune mechanisms against virus-associated leukemia and fibrosarcoma. Cellular Immunology 81:157–168
    [Google Scholar]
25. Manjunath R., Graziano R. F., Green W. R. 1986; The specificity of H-2-restricted cytotoxic T lymphocytes directed to AKR/Gross leukemia virus-induced tumors. III. Coordinate alterations in viral gp70 antigen expression and restoration of CTL-susceptibility to insusceptible variant tumors. Journal of Immunology 136:2271–2279
    [Google Scholar]
26. Manzanec M. B., Nedrud J. G., Lamm M. E. 1987; Immunoglobulin A monoclonal antibodies protect against Sendai virus. Journal of Virology 61:2624–2626
    [Google Scholar]
27. Martin S., Rouse B. T. 1990; The control of human herpesvirus infections by cytotoxic T lymphocytes (CTL): a comparison to AIDS virus specific CTL. In Herpesviruses, the Immune System and AIDS pp 73–98 Edited by Aurelian L. Norwell: Kluwer Academic;
    [Google Scholar]
28. Mathes L. E., Olsen R. G., Hebebrand L. C., Hoover E. A., Schaller J. P. 1978; Abrogation of lymphocyte blastogenesis by a feline leukaemia virus protein. Nature, London 274:687–689
    [Google Scholar]
29. Mathes L. E., Olsen R. G., Hebebrand L. C., Hoover E. A., Schaller J. P., Adams P. W., Nichols W. S. 1979; Immunosuppressive properties of a virion polypeptide, a 15, 000 dalton protein from feline leukemia virus. Cancer Research 39:950–955
    [Google Scholar]
30. Nick S., Klaws J., Friebel K., Birr C., Hunsmann G., Bayer H. 1990; Virus neutralizing and enhancing epitopes characterized by synthetic oligopeptides derived from the feline leukaemia virus glycoprotein sequence. Journal of General Virology 71:77–83
    [Google Scholar]
31. Nunberg J. H., Rodgers G., Gilbert J. H., Snead R. M. 1984; Methods to map antigenic determinants recognized by monoclonal antibodies: localization of a determinant of virus neutralization on the feline leukemia virus envelope gp70. Proceedings of the National Academy of Sciences, U.S.A. 81:3675–3679
    [Google Scholar]
32. Nunberg J. H., Wright D. K., Cole G. E., Petrovskis E. A., Post L. E., Compton T., Gilbert J. H. 1989; Identification of the thymidine kinase gene of feline herpesvirus: use of degenerate oligonucleotides in the polymerase chain reaction to isolate herpesvirus gene homologs. Virology 63:3240–3249
    [Google Scholar]
33. Olsen R. G., Hoover E. A., Schaller J. P., Mathes L. E., Wolff L. H. 1977; Abrogation of resistance to feline coronavirus disease by immunization with killed feline leukemia virus. Cancer Research 37:2082–2085
    [Google Scholar]
34. Osterhaus A., Weijer K., UytdeHaag F., Knell P., Jarrett O., Sundquist B., Morein B. 1985; Induction of protective immune response in cats by vaccination with feline leukemia virus ISCOM. Journal of Immunology 135:591–596
    [Google Scholar]
35. Osterhaus A., Weijer K., UytdeHaag F., Knell P., Jarrett O., Akerblom L., Morein B. 1989; Serological responses in cats vaccinated with FeLV ISCOM and an inactivated FeLV vaccine. Vaccine 7:137–141
    [Google Scholar]
36. Pedersen N. C., Johnson L., Bird C., Theilen G. H. 1986; Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective. Veterinary Immunology and Immunopathology 11:123–148
    [Google Scholar]
37. Pierce N. F., Cray W. C. 1981; Cellular dissemination of priming for a mucosal immune response to cholera toxin in rats. Journal of Immunology 127:2461–2464
    [Google Scholar]
38. Pierce N. F., Cray W. C. 1982; Determinants of localization, magnitude, and duration of a specific mucosal IgA plasma cell response in enterically immunized rats. Journal of Immunology 128:1311–1315
    [Google Scholar]
39. Rojko J. L., Hoover E. A., Mathes L. E., Olsen R. G., Schaller J. P. 1979; Pathogenesis of experimental feline leukemia virus infection. Journal of the National Cancer Institute 63:759–768
    [Google Scholar]
40. Rosenthal K. L., Zinkernagel R. N. 1980; Cross-reactive cytotoxic T cells to serologically distinct vesicular stomatitis virus. Journal of Immunology 144:2301–2310
    [Google Scholar]
41. Russell P. H., Jarrett O. 1978; The specificity of neutralizing antibodies to feline leukemia viruses. International Journal of Cancer 21:768–773
    [Google Scholar]
42. Salerno D. A., Lehman F. D., Casson U. M., Hilleman M. R. 1978; Feline leukemia virus envelope glycoprotein vaccine: preparation and evaluation of immunizing potency in guinea pig and cat. Journal of the National Cancer Institute 61:1487–1491
    [Google Scholar]
43. Sarma P., Log T. 1973; Subgroup classification of feline leukemia and sarcoma viruses by viral interference and neutralisation tests. Virology 54:160–169
    [Google Scholar]
44. Schaller J. P., Hoover E. A., Olsen R. G. 1977; Active and passive immunization of cats with inactivated feline oncornsaviruses. Journal of the National Cancer Institute 59:1441–1450
    [Google Scholar]
45. Takeda A., Tuazon C. U., Ennis F. A. 1988; Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 242:580–583
    [Google Scholar]
46. Theilen G. H., Kawakami T. G., Rush J. D., Munn R. J. 1969; Replication of cat leukemia virus in cell suspension cultures. Nature, London 222:589–590
    [Google Scholar]
47. Thomsen D. R., Meyer A. L., Post L. E. 1992; Expression of feline leukaemia virus gp85 and gag proteins and assembly into virus-like particles using the baculovirus expression vector system. Journal of General Virology 73:1819–1824
    [Google Scholar]
48. Van Der Hoorn F. A., Lahaye T., Muller V., Ogle M. A., Engers H. D. 1985; Characterization of gp85gag as an antigen recognized by Moloney leukemia virus-specific cytolytic T cell clones that function in vivo. Journal of Experimental Medicine 162:128–144
    [Google Scholar]
49. Van Zijl M., Wensvoort G., De Kluyver E., Hulst M., Van Der Gulden H., Gielkens A., Berns A., Moormann R. 1991; Live attenuated pseudorabies virus expressing envelope glycoprotein E1 of hog cholera vius protects swine against both pseudorabies and hog cholera. Journal of Virology 65:2761–2765
    [Google Scholar]
50. Zweerink H. J., Courtneidge S. A., Skehel J. J., Crumpton M. J., Askonas B. A. 1977; Cytotoxic T cells kill influenza virus-infected cells but do not distinguish between serologically distinct A viruses. Nature, London 267:354–361
    [Google Scholar]